Given that VEGF, EGF, and MCP-1 are often elevated in many cancers [142,143,144,145], KMT may be an effective way to support the action of certain cancer therapies, along with using the glucose-ketone index (GKI) calculator to measure therapeutic efficacy in metabolic management of brain cancers and likely other cancers [146]. The gene discussed is CCL2; the disease is cancer.